Thursday, August 27, 2026
HomeTagsPCSK9 inhibitor

PCSK9 inhibitor

Everest Medicines Announces NMPA Acceptance of the BLA for LEROCHOL(R), Offering a New Treatment Option for Hypercholesterolemia

Everest Medicines announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics